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Abstracts 
N0-73. TRIMl 1 IS A NOVEL AND SPECIFIC GLIOMA 
STEM-LIKE CELL MARKER THAT ALSO PLAYS A ROLE IN
GLIOMA BIOLOGY THROUGH THE EGFR PATHWAY 
Kaijun Di, Mark Linskey, and Daniela A. Bota; UC Irvine, Orange, CA 
SUMMARY: Expression of tripartite motif-containing protein 11 ( 
TRIMll), a member of the TRIM/RBCC family of E3 ubiquitin ligases, is 
upregulated in high grade glioma-derived tumor stem-like cells (GSCs) 
while remaining low in glioblastoma multiforme (GBM) cell lines, low-grade 
glioma-derived GSCs, and normal neural stem/progenitor cells (NSCs) 
studied in vitro. The expression pattern of TRIM 11 strongly correlated with 
that of the stem cell markers CD 133 and nestin in GSCs. Knockdown of 
TRIMll inhibited proliferation, migration, and invasion of glioma cells 
and caused decreased EGFR levels and MAPK activity. These findings 
suggest that TRIM 11 can be used to specifically identify and potentially 
target GBM-derived GSCs while selectively sparing normal NSCs and that 
TRIM 11 also functions as an oncogene that promotes tumor growth and inva­
sion. SIGNIFICANCE: GSCs are important for tumor initiation, resistance to 
conventional therapies, and tumor recurrence after therapy. Unfortunately, 
all reported markers for identifying and potentially targeting these cells are 
shared in common with normal NSCs. Damage to normal NSCs resulting 
from glioma therapies can produce profound cognitive side effects. The poten­
tial to selectively identify and target GSCs while sparing NSCs is an important 
advance. In addition, identifying TRIMl 1 as a novel new oncogene for malig­
nant glioma with linkage into the EGFR signaling pathway expands our 
knowledge of TRIM 11 biology and opens the door to exploring a potential 
new translational target for malignant glioma therapy. HIGHLIGHTS: 1) 
TRIM11 is up-regulated in high-grade glioma GSCs, but not in low grade 
GSCs and NSCs studied in appropriate in vitro conditions relative to their 
cell type. 2) The expression pattern of TRIM11 strongly correlates with that 
of CD133 and nestin in GSCs. 3) TRIMll promotes the proliferation, 
migration, and invasion of malignant glioma cells. 4) TRIMll modulates 
EGFR expression, possibly through regulating the transcription of HB-EGF 
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